Microbicide dosage forms

Current Topics in Microbiology and Immunology

Volumn 383, Issue , 2014, Pages 27-54

  Rohan, L C ^a   Devlin, B ^b   Yang, H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ASTODRIMER; CARRAGEENAN; CELLULOSE DERIVATIVE; DAPIVIRINE; DAPIVIRINE PLUS DS 003; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ESTRADIOL; ESTRADIOL ACETATE; ETHINYLESTRADIOL PLUS ETONOGESTREL; HYDROXYLETHYLCELLULOSE; MICROBICIDE; PLACEBO; POLYETHYLENE; POLYMACON; POLYPROPYLENE; SILASTIC; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DOSAGE FORM;

ANTIVIRAL ACTIVITY; ARTICLE; COITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROSPINNING; ELECTROSPUN FIBER; FLOW KINETICS; GASTROINTESTINAL TOXICITY; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; LIVER TOXICITY; MECHANICAL STIMULATION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SILCS DIAPHRAGM; TABLET; THERMOPLASTIC RING; UROGENITAL ATROPHY; UROGENITAL TRACT DISEASE; UTERINE CERVIX CAP; VAGINA PH; VAGINA RING; VAGINAL FILM; VIRUS INHIBITION; VIRUS TRANSMISSION; CLINICAL TRIAL (TOPIC); DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84921696480     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2013_357     Document Type: Article

References (157)

1. Abdool Karim Q, Abdool Karim SS et al (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996):1168–1174
2. Abdool Karim SS, Richardson BA et al (2011) Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7):957–966
3. Adriaens E, Remon JP (2008) Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis 35(5):512–516
4. Agashe H, Hu M et al (2012) Formulation and delivery of microbicides. Curr HIV Res 10(1):88–96
5. Akil A, Parniak MA et al (2011) Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res 1(3):209–222
6. Alexander NJ, Baker E et al (2004) Why consider vaginal drug administration? Fertil Steril 82(1):1–12
7. Austin GD, Colburn TJ et al (1998) Contraceptive diaphragm. US patent Number 5, 900
8. Ayres C, Bowlin GL et al (2006) Modulation of anisotropy in electrospun tissue-engineering scaffolds: analysis of fiber alignment by the fast Fourier transform. Biomaterials 27(32):5524–5534
9. Ball C, Krogstad E et al (2012) Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One 7(11):e49792
10. Baloglu E, Ay Senyigit Z et al (2011) In vitro evaluation of mucoadhesive vaginal tablets of antifungal drugs prepared with thiolated polymer and development of a new dissolution technique for vaginal formulations. Chem Pharm Bull (Tokyo) 59(8):952–958
11. Balzarini J, Van Damme L (2007) Microbicide drug candidates to prevent HIV infection. Lancet 369(9563):787–797
12. Beigi R, Noguchi L et al (2011) Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. J Infect Dis 204(10):1527–1531
13. Bradshaw CS, Pirotta M et al (2012) Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS One 7(4):e34540
14. Buckheit RW Jr, Watson KM et al (2010) Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res 85(1):142–158
15. Cao H, Jiang X et al (2010) RNA interference by nanofiber-based siRNA delivery system. J Control Release 144(2):203–212
16. Chandra A, Mosher WD et al (2011) Sexual behavior, sexual attraction, and sexual identity in the United States: data from the 2006–2008 national survey of family growth. Natl Health Stat Rep 36:1–36
17. Chatterjee A, Bhowmik B et al (2010) Prolong release bioadhesive vaginal film of anti-HIV drug (Zidovudine): formualtion and in-vitro evaluation. Int J Pharm Sci Res 1(3):28–37
18. Chen D, Sun K et al (2012) pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system. Int J Nanomed 7:2621–2630
19. Chiu JB, Liu C et al (2007) Functionalization of poly(L-lactide) nanofibrous scaffolds with bioactive collagen molecules. J Biomed Mater Res A 83(4):1117–1127
20. Clark M, Hadd S et al (2011) Pharmacokinetics of a fast-dissolve tenofovir vaginal tablet in a rabbit model AAPS meeting. Washington, DC
21. Clark M, Doncel G et al (2012) Development and preclinical pharmacokinetic evaluation of a tenofovir fast-dissolve vaginal tablet. Microbicides 2012, Sydney, Australia
22. Cole AM, Patton DL et al (2010) The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One 5(11):e15111
23. Courtney T, Sacks MS et al (2006) Design and analysis of tissue engineering scaffolds that mimic soft tissue mechanical anisotropy. Biomaterials 27(19):3631–3638
24. Creatsas G, Guerrero E et al (2001) A multinational evaluation of the efficacy, safety and acceptability of the protectaid contraceptive sponge. Eur J Contracept Reprod Health Care 6(3):172–182
25. Cui W, Li X et al (2006) Investigation of drug release and matrix degradation of electrospun poly(DL-lactide) fibers with paracetanol inoculation. Biomacromolecules 7(5):1623–1629
26. Dobaria N, Mashru R (2010) Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clindamycin phosphate. Pharm Dev Technol 15(4):405–414
27. Dobaria NB, Badhan AC et al (2009) A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization. AAPS PharmSciTech 10(3):951–959
28. Duncan G (1970) Medicated devices and methods. US Patent Number 3, 439
29. Escobar-Chavez JJ, Lopez-Cervantes M et al (2006) Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. J Pharm Pharm Sci 9(3):339–358
30. Fan M, Ferguson L, Rohan L, Meyn L, Hillier S (2011) Social and behavioural aspects of prevention poster session 9: Women P2-S9.06 Vaginal film microbicides for HIV prevention: a mixed methods study of women’s preferences. Sex Transm Infect 87:A263. http:// sti.bmj.com/content/87/Suppl_1/A263.1. doi:10.1136/sextrans-2011-050108.392
31. Fares H, Zatz J (1995) Measurement of drug release from topical gels using two types of apparatus. Pharm Technol 19(1):52–58
32. FDA (1997) Guidance for industry, nonsterile semisolid dosage forms, scale-up and postapproval changes: chemistry, manufacturing, and controls. In vitro release testing and in vivo bioequivalence documentation
33. Feng K, Sun H et al (2010) Novel antibacterial nanofibrous PLLA scaffolds. J Control Release 146(3):363–369
34. Fetherston SM, Malcolm RK et al (2010) Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Ther Deliv 1(6):785–802
35. Fletcher P, Harman S et al (2009) Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 53(2):487–495
36. Foran TM (2003) New contraceptive choices across reproductive life. Med J Aust 178(12):616–620
37. Forbes CJ, Lowry D et al (2011) Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 156(2):161–169
38. Gallagher SJ, Trottet L et al (2003) Ketoprofen: release from, permeation across and rheology of simple gel formulations that simulate increasing dryness. Int J Pharm 268(1–2):37–45
39. Garg S, Anderson RA et al (2001) Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 64(1):67–75
40. Garg S, Vermani K et al (2005) Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res 22(4):584–595
41. Garg S, Goldman D et al (2010) Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 88(Suppl 1):S19–S29
42. Gohel MC, Jogani PD (2005) A review of co-processed directly compressible excipients. J Pharm Pharm Sci 8(1):76–93
43. Greiner A, Wendorff JH (2007) Electrospinning: a fascinating method for the preparation of ultrathin fibers. Angew Chem Int Ed Engl 46(30):5670–5703
44. Gupta P, Vermani K et al (2002) Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov Today 7(10):569–579
45. Gupta KM, Pearce SM et al (2008) Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 97(10):4228–4239
46. Gupta J, Othman A et al (2011) Development and validation of a HPLC method for simultaneous determination of dapivirine and DS003 in combination microbicide tablet. Curr Pharm Anal 7(1):21–26
47. Ham AS, Rohan LC et al (2012) Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res 29(7):1897–1907
48. Han YA, Singh M et al (2007) Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. Contraception 76(2):132–138
49. Hariharan M, Bogue BA (2009) Orally dissolving film strips (ODFS): the final evolution of orally dissolving dosage forms. Drug Deliv Technol 9(2):24–29
50. Herrera C, Shattock RJ (2013) Candidate microbicides and their mechanisms of action. Curr Top Microbiol Immunol. http://link.springer.com/chapter/10.1007%2F82_2013_326. doi:10.1007/82_2013_326. Epub ahead of print
51. Holt JDS, Nuttall JP (2013) Preclinical safety evaluation. Curr Top Microbiol Immunol. doi:10.1007/82_2013_327
52. Huang ZM, He CL et al (2006) Encapsulating drugs in biodegradable ultrafine fibers through coaxial electrospinning. J Biomed Mater Res A 77(1):169–179
53. Hussain A, Ahsan F (2005) The vagina as a route for systemic drug delivery. J Control Release 103(2):301–313
54. Ionescu LC, Lee GC et al (2010) An anisotropic nanofiber/microsphere composite with controlled release of biomolecules for fibrous tissue engineering. Biomaterials 31(14):4113–4120
55. Iyer V, Poddar SS (2008) Update on nonoxynol-9 as vaginal spermicide. Eur J Contracept Reprod Health Care 13(4):339–350
56. Jespers VA, Van Roey JM et al (2007) Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr 44(2):154–158
57. Jiang H, Hu Y et al (2005) A facile technique to prepare biodegradable coaxial electrospun nanofibers for controlled release of bioactive agents. J Control Release 108(2–3):237–243
58. Jin Q, Wei G et al (2008) Nanofibrous scaffolds incorporating PDGF-BB microspheres induce chemokine expression and tissue neogenesis in vivo. PLoS One 3(3):e1729
59. Joglekar NS, Joshi SN et al (2006) Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India–Phase I study. Indian J Med Res 123(4):547–552
60. Johansson ED (2000) The return of the pharmaceutical industry to the market of contraception. Steroids 65(10–11):709–711
61. Johnson TJ, Gupta KM et al (2010) Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 39(4):203–212
62. Johnson TJ, Srinivasan P et al (2012) Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 56(3):1291–1299
63. Joshi SN, Katti U et al (2005) Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India. Trans R Soc Trop Med Hyg 99(10):769–774
64. Kalichman SC, Simbayi LC et al (2009) Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sex Transm Infect 85(6):411–415
65. Kawarkhe S, Poddar SS (2010) Designing of the mucoadhesive intravaginal spermicidal films. Indian J Pharm Sci 72(5):652–655. doi:10.4103/0250-474X.78540 (PMCID: PMC3116316)
66. Keller MJ, Madan RP et al (2011) A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 6(1):e16475
67. Kidoaki S, Kwon IK et al (2005) Mesoscopic spatial designs of nano- and microfiber meshes for tissue-engineering matrix and scaffold based on newly devised multilayering and mixing electrospinning techniques. Biomaterials 26(1):37–46
68. Kidoaki S, Kwon IK et al (2006) Structural features and mechanical properties of in situ-bonded meshes of segmented polyurethane electrospun from mixed solvents. J Biomed Mater Res B Appl Biomater 76(1):219–229
69. Kim HS, Yoo HS (2010) MMPs-responsive release of DNA from electrospun nanofibrous matrix for local gene therapy: in vitro and in vivo evaluation. J Control Release 145(3):264–271
70. Kiser PF, Johnson TJ et al (2012) State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 14(1):62–77
71. Kumar P, Sanghvi P, Collins CC (1993) Comparison of diffusion studies of hydrocortisone between the Franz cell and the enhancer cell. Drug Dev Ind Pharm 19(13):1573–1585
72. Lacey CJ, Woodhall S et al (2010) Unacceptable side-effects associated with a hyperosmolar vaginal microbicide in a phase 1 trial. Int J STD AIDS 21(10):714–717
73. Lai BE, Geonnotti AR et al (2010) Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Antiviral Res 88(2):143–151
74. Liang D, Luu YK et al (2005) In vitro non-viral gene delivery with nanofibrous scaffolds. Nucleic Acids Res 33(19):e170
75. Lichtman AS, Davajan V et al (1973) C-film: a new vaginal contraceptive. Contraception 8(4):291–297
76. Loxley A, Mitchnick M et al (2011) Ethylene vinyl acetate intravaginal rings for the simultaneous delivery of the antiretroviral UC781 and contraceptive levonorgestrel. Drug Deliv Transl Res 1(3):247–255
77. Luong-Van E, Grondahl L et al (2006) Controlled release of heparin from poly(epsiloncaprolactone) electrospun fibers. Biomaterials 27(9):2042–2050
78. Macht DI (1918) On the absorption of drugs and poisons through the vagina. J Pharmacol Exp Ther 10:509–522
79. Mahalingam A, Smith E et al (2010) Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res 27(11):2478–2491
80. Mahalingam A, Simmons AP et al (2011) Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother 55(4):1650–1660
81. Major I, Boyd P et al (2012) A dapivirine releasing contraceptive diaphragm. Microbicides 2012, Sydney, Australia.
82. Major I, Lowry D et al (2010) Development of a microbicide-releasing diaphragm as an HIV prevention strategy. Conf Proc IEEE Eng Med Biol Soc 2010:1089–1092
83. Malcolm RK, Edwards KL et al (2010) Advances in microbicide vaginal rings. Antiviral Res 88(Suppl 1):S30–39
84. Maretschek S, Greiner A et al (2008) Electrospun biodegradable nanofiber nonwovens for controlled release of proteins. J Control Release 127(2):180–187
85. Martin HL, Richardson BA et al (1999) Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 180(6):1863–1868
86. Mauck CK, Allen S et al (1997a) An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9. Contraception 56(2):103–110
87. Mauck CK, Baker JM et al (1997b) A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy. Contraception 56(2):89–96
88. Mauck CK, Baker JM et al (1997c) A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopy. Contraception 56(2):97–102
89. Mauck RL, Baker BM et al (2009) Engineering on the straight and narrow: the mechanics of nanofibrous assemblies for fiber-reinforced tissue regeneration. Tissue Eng Part B Rev 15(2):171–193
90. Mayer KH, Maslankowski LA et al (2006) Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20(4):543–551
91. McGowan I, Hoesley C et al (2013) A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS One 8(4):e60147
92. Minces LR, McGowan I (2010) Advances in the development of microbicides for the prevention of HIV infection. Curr Infect Dis Rep 12(1):56–62
93. Moench TR, Mumper RJ et al (2010) Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis 10:331
94. Morrow KM, Hendrix C (2010) Clinical evaluation of microbicide formulations. Antiviral Res 88(Suppl 1):S40–46
95. Moss JA, Malone AM et al (2012) Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother 56(2):875–882
96. Nel A, Smythe S et al (2009a) Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 51(4):416–423
97. Nel AM, Coplan P et al (2009b) Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 23(12):1531–1538
98. Nel AM, Coplan P et al (2010a) Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 26(11):1181–1190
99. Nel AM, Smythe SC et al (2010b) Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 55(2):161–169
100. Nel AM, Mitchnick LB et al (2011) Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. J Womens Health (Larchmt) 20(8):1207–1214
101. Nerurkar NL, Elliott DM et al (2007) Mechanics of oriented electrospun nanofibrous scaffolds for annulus fibrosus tissue engineering. J Orthop Res 25(8):1018–1028
102. Neurath AR, Strick N et al (1999) Design of a ‘‘microbicide’’ for prevention of sexually transmitted diseases using ‘‘inactive’’ pharmaceutical excipients. Biologicals 27(1):11–21
103. Neurath AR, Strick N et al (2001) Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 1:17
104. Neurath AR, Strick N et al (2003) Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect Dis 3:27
105. Novak A, de la Loge C et al (2003) The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 67(3):187–194
106. O’Dowd MJ (ed) (2001) The history of medications for women: materia medica woman. Taylor & Francis, London
107. Okuda T, Tominaga K et al (2010) Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. J Control Release 143(2):258–264
108. Owen DH, Peters JJ et al (2003) Effect of temperature and pH on contraceptive gel viscosity. Contraception 67(1):57–64
109. Pham Q, Sharma U et al (2006) Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng 12(5):1197–1211
110. Politz ML, Timpa JD et al (1994) Non-aqueous gel permeation chromatography of wheat starch in dimethylacetamide (DMAC) and LiCl: extrusion-induced fragmentation. Carbohydr Polym 24:91–99
111. Rad M, Kluft C et al (2006) Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol 195(1):72–77
112. Reeves JD, Piefer AJ (2005) Emerging drug targets for antiretroviral therapy. Drugs 65(13):1747–1766
113. Reilly B, Bruner S (2004) Silicones as a material of choice for drug delivery applications. In: 31st annual meeting and exposition of the controlled release society, Honolulu, Hawaii
114. Roddy RE, Zekeng L et al (1998) A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 339(8):504–510
115. Roumen FJ, Apter D et al (2001) Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 16(3):469–475
116. Roy S, Gourde P et al (2001) Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. Antimicrob Agents Chemother 45(6):1671–1681
117. Sam AP, Fokkens JG (1997) Drug delivery system: adding therapeutic and economic value to pharmacotherapy part 2. Pharm Tech Eur 9:58–66
118. Sassi AB, Isaacs CE et al (2008) Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J Pharm Sci 97(8):3123–3139
119. Sassi AB, Cost MR et al (2011) Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product. Antimicrob Agents Chemother 55(5):2282–2289
120. Saxena BB, Han YA et al (2009) Sustained release of microbicides by newly engineered vaginal rings. AIDS 23(8):917–922
121. Schwartz JL, Ballagh SA et al (2008a) SILCS diaphragm: postcoital testing of a new single-size contraceptive device. Contraception 78(3):237–244
122. Schwartz JL, Kovalevsky G et al (2008b) A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex Transm Dis 35(4):414–419
123. Seager H (1998) Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 50(4):375–382
124. Seattle King County Department of Public Health (2000) What is the STD-HIV connection? Accessed June 2000. http://www.metrokc.gov/health/apu/healthed/Powr/HIV_STD/sld003.htm
125. Seeras RC (1995) Induction of labor utilizing vaginal vs. intracervical prostaglandin E2. Int J Gynaecol Obstet 48(2):163–167
126. Seeras RC, Olatunbosun OA et al (1995) Induction of labor using prostaglandin E2 (PGE2) vaginal gel in triacetin base. An efficacy study comparing two dosage regimens. Clin Exp Obstet Gynecol 22(2):105–110
127. Shah VP, Elkins J et al (1989) Determination of in vitro drug release from hydrocortisone creams. Int J Pharm 53(1):53–59
128. Siewert M, Dressman J et al (2003) FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech 4(1):E7
129. Skoler-Karpoff S, Ramjee G et al (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372(9654):1977–1987
130. Song Y, Wang Y et al (2004) Mucosal drug delivery: membranes, methodologies, and applications. Crit Rev Ther Drug Carrier Syst 21(3):195–256
131. Stitzel J, Liu J et al (2006) Controlled fabrication of a biological vascular substitute. Biomaterials 27(7):1088–1094
132. Sudeendra B, Umme H et al (2010) Development and characterization of bioadhesive vaginal films of clotrimazole for vaginal candidiasis. Acta Pharmaceutica Sciencia 52:417–426
133. Szycher M (1988) Biostability of polyurethane elastomers: a critical review. J Biomater Appl 3(2):297–402
134. Taepaiboon P, Rungsardthong U et al (2006) Drug-loaded electrospun mats of poly(vinyl alcohol) fibres and their release characteristics of four model drugs. Nanotechnology 17(9):2317–2329
135. Tamburic S, Craig DQ (1996) The effects of ageing on the rheological, dielectric and mucoadhesive properties of poly(acrylic acid) gel systems. Pharm Res 13(2):279–283
136. Tan AR, Ifkovits JL et al (2008) Electrospinning of photocrosslinked and degradable fibrous scaffolds. J Biomed Mater Res A 87(4):1034–1043
137. Tao W, Richards C et al (2008) Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses 24(7):925–929
138. Theron A, Zussman E et al (2001) Electrostatic field-assisted alignment of electrospun nanofibres. Nanotechnology 12:384–390
139. Thyssen H, Bidmead J et al (2001) A new intravaginal device for stress incontinence in women. BJU Int 88(9):889–892
140. Trifonova RT, Pasicznyk JM et al (2006) Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob Agents Chemother 50(12):4005–4010
141. Turpin JA (2011) Topical microbicides to prevent the transmission of HIV: formulation gaps and challenges. Drug Deliv Transl Res 1(3):194–200
142. van Laarhoven JA, Kruft MA et al (2002a) Effect of supersaturation and crystallization phenomena on the release properties of a controlled release device based on EVA copolymer. J Control Release 82(2–3):309–317
143. van Laarhoven JA, Kruft MA et al (2002b) In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm 232(1–2):163–173
144. Ventuneac A, Carballo-Dieguez A et al (2010) Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav 14(3):618–628
145. Vermani K, Garg S (2000) The scope and potential of vaginal drug delivery. Pharm Sci Technolo Today 3(10):359–364
146. Virley P, Yarwood R (1990) Zydis-a novel, fast dissolving dosage form. Manufact Chemist 61:36–37
147. Vondrak B, Barnhart S (2008) Dissolvable films: dissolvable films for flexible product format in drug delivery. Pharm Technol. Accessed http://www.pharmtech.com/pharmtech/Article/Dissolvable-Films-Dissolvable-Films-for-Flexible-P/ArticleStandard/Article/detail/505380
148. Wang J, Chen C et al (2010) Effect of experimental parameters on the formation of chitosan- Poly(acrylic acid) nanofibrous scaffolds and evaluation of their potential application as DNA carrier. J Appl Polym Sci 155(1769):1769–1780
149. Weber J, Desai K et al (2005) The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med 2(5):e142
150. Wei G, Jin Q et al (2006) Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J Control Release 112(1):103–110
151. Wichterle O, Lim D (1960) Hydrophilic gels for biological use. Nature 185(4706):117–118
152. Woolfson A, Elliott G et al (1999) Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester. J Control Release 61(3):319–328
153. Yang H, Parniak MA et al (2008) Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. AAPS J 10(4):606–613
154. Yoo JW, Dharmala K et al (2006) The physicodynamic properties of mucoadhesive polymeric films developed as female controlled drug delivery system. Int J Pharm 309(1–2):139–145
155. Yoo JW, Acharya G et al (2009) In vivo evaluation of vaginal films for mucosal delivery of nitric oxide. Biomaterials 30(23–24):3978–3985
156. Zhang W, Parniak MA et al (2012) Formulation, optimization and characterization of a vaginal film containing EFdA, a novel nucleoside reverse transcriptase inhibitor (NRTI), for HIV prevention. 2012
157. Microbicides, Sydney, Australia Zhang YZ, Wang X et al (2006) Coaxial electrospinning of (fluorescein isothiocyanateconjugated bovine serum albumin)-encapsulated poly(epsilon-caprolactone) nanofibers for sustained release. Biomacromolecules 7(4):1049–1057